Skip to main content
Fig. 1 | Genome Medicine

Fig. 1

From: Longitudinal analysis of treatment-induced genomic alterations in gliomas

Fig. 1

Clinical progression of the presented case. Treatments are represented with colored bars: temozolomide treatment in pink; vandetanib (targeted EGFR treatment) in purple, carboxyamidotriazole orotate (CTO; targeted phosphoinositide 3-kinase treatment) in yellow, immunotherapy in dark blue, hydroxurea in red, radiation in light blue, and bevacizumab in magenta

Back to article page
\